Description
The ProbeSeq Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) Nanobody is a recombinant single-domain antibody (VHH) engineered for high-affinity and selective binding to human UCH-L1, a neuron-specific cytoplasmic enzyme released following neuronal damage. This nanobody supports research-use diagnostic assay development, neuroinjury biomarker detection, and advanced biosensor integration.
UCH-L1 is widely recognized as a sensitive biomarker of neuronal injury and is extensively studied in traumatic brain injury, stroke, and neurodegenerative disorders. Circulating UCH-L1 levels reflect neuronal cell damage and blood–brain barrier disruption, making sensitive detection essential for neurodiagnostic research and rapid brain injury monitoring technologies.
Derived from camelid heavy-chain antibody architecture, this nanobody consists of a single monomeric VHH domain (~15 kDa) providing strong antigen recognition, rapid binding kinetics, and high structural stability. Compared with conventional antibodies, nanobodies offer superior thermal stability, efficient surface immobilization, and reduced steric hindrance, enabling high-performance detection in electrochemical biosensors, microfluidic platforms, and miniaturized diagnostic systems.
Typical assay workflows use sample input volumes ranging from approximately 5–50 µL depending on platform configuration and detection method. The nanobody is compatible with serum, plasma, cerebrospinal fluid, and buffered biological samples following appropriate assay optimization.
What’s Included
Recombinant anti-UCH-L1 single-domain VHH nanobody
Sequence and expression documentation for research traceability
Reconstitution and handling guidelines
Custom affinity tags (His-tag, biotin, Fc fusion), labeling options, and bulk production available upon request
Target Strategy
Engineered for high binding specificity to UCH-L1 protein epitopes
Minimal cross-reactivity with related deubiquitinating enzymes
Stable binding under physiological conditions
Compatible with biosensor surface functionalization and immunoassay workflows
Product Format
Lyophilized format
Delivered dry for enhanced stability
Reconstitute in PBS or preferred buffer
Solution format
Supplied in PBS-based storage buffer
Typical concentration range 0.5–1 mg/mL
Tagged variants available upon request
Performance Orientation
Electrochemical biosensors
Neuroinjury biomarker detection platforms
Microfluidic and lab-on-chip systems
Surface immobilization workflows
Optical and fluorescence detection platforms
Point-of-care neurological diagnostic research devices
Quality Control
Sequence confirmation
Purity validation (SDS-PAGE / chromatography)
Binding verification testing
Concentration determination
Manufacturing quality review
Certificate of Analysis (CoA) available upon request
Applications
Traumatic brain injury biomarker detection research
Stroke and neuronal injury studies
Neurodegeneration research
Immunoassay and biosensor development
Microfluidic diagnostic platform integration
Point-of-care neurological monitoring research
Storage
Store at –20 °C for long-term storage or 4 °C for short-term use.
Lyophilized nanobody stable for up to 12 months under recommended conditions. Avoid repeated freeze–thaw cycles.
